The Series C financing accompanies a strategic collaboration with UCB, which covers Synosia’s lead compounds SYN-115 and SYN-118 in development to treat Parkinson’s disease.
Synosia Therapeutics, a Basel, Switzerland-based biotherapeutics company focused on neurology and psychiatry, has raised $30m in a Series C financing round.
The round was led by new investor UCB, which committed $20m, with participation from existing investors Versant Ventures, 5Am Ventures, Novo A/S, Aravis Venture, Investor Growth Capital and Swiss Helvetia Fund, which committed $10m.
As part of the agreement, UCB’s President of North American Operations Greg Duncan and Executive Vice President of Drug Discovery and President of UCB New Medicines Ismail Kola will join the company’s board of directors.
Synosia currently has six clinical-stage compounds in its pipeline for neurological and psychiatric diseases, including Parkinson’s and Alzheimer’s disease.